JPS6260369B2 - - Google Patents

Info

Publication number: JPS6260369B2
Authority: JP; Japan
Prior art keywords: blood; neosugar; sucrose; weeks; lipids
Prior art date: 1982-11-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP19236282A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5982313A (ja

Inventor

Tetsutaro Niisato

Ueto Takeda

Hidemasa Hidaka

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Meiji Seika Kaisha Ltd

Original Assignee

Meiji Seika Kaisha Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-11-04

Filing date

1982-11-04

Publication date

1987-12-16

1982-11-04 Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd

1982-11-04 Priority to JP19236282A priority Critical patent/JPS5982313A/ja

1984-05-12 Publication of JPS5982313A publication Critical patent/JPS5982313A/ja

1987-12-16 Publication of JPS6260369B2 publication Critical patent/JPS6260369B2/ja

Status Granted legal-status Critical Current

Links

150000002632 lipids Chemical class 0.000 claims description 21
235000000346 sugar Nutrition 0.000 claims description 11
229930091371 Fructose Natural products 0.000 claims description 9
239000005715 Fructose Substances 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
150000002482 oligosaccharides Chemical class 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 5
239000003638 chemical reducing agent Substances 0.000 claims description 5
229920001542 oligosaccharide Polymers 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
238000001802 infusion Methods 0.000 claims description 2
239000008188 pellet Substances 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
229930006000 Sucrose Natural products 0.000 description 15
210000004369 blood Anatomy 0.000 description 15
239000008280 blood Substances 0.000 description 15
239000005720 sucrose Substances 0.000 description 15
235000012000 cholesterol Nutrition 0.000 description 11
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
230000037396 body weight Effects 0.000 description 10
150000003626 triacylglycerols Chemical class 0.000 description 9
150000003904 phospholipids Chemical class 0.000 description 8
208000031226 Hyperlipidaemia Diseases 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
241000700159 Rattus Species 0.000 description 7
230000007423 decrease Effects 0.000 description 7
206010012601 diabetes mellitus Diseases 0.000 description 7
208000004930 Fatty Liver Diseases 0.000 description 6
206010019708 Hepatic steatosis Diseases 0.000 description 6
206010020772 Hypertension Diseases 0.000 description 6
235000005911 diet Nutrition 0.000 description 6
230000037213 diet Effects 0.000 description 6
208000010706 fatty liver disease Diseases 0.000 description 6
231100000240 steatosis hepatitis Toxicity 0.000 description 6
208000008589 Obesity Diseases 0.000 description 5
241000700157 Rattus norvegicus Species 0.000 description 5
238000009534 blood test Methods 0.000 description 5
150000001720 carbohydrates Chemical class 0.000 description 5
230000000694 effects Effects 0.000 description 5
235000020824 obesity Nutrition 0.000 description 5
239000000126 substance Substances 0.000 description 5
125000000185 sucrose group Chemical group 0.000 description 5
238000012360 testing method Methods 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
239000008103 glucose Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
238000011699 spontaneously hypertensive rat Methods 0.000 description 4
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
229960001052 streptozocin Drugs 0.000 description 4
XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
238000010171 animal model Methods 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
108010042889 Inulosucrase Proteins 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000000034 method Methods 0.000 description 2
238000013116 obese mouse model Methods 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
238000004159 blood analysis Methods 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000021092 sugar substitutes Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000006276 transfer reaction Methods 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1

Landscapes

Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP19236282A 1982-11-04 1982-11-04 体内脂質減少剤 Granted JPS5982313A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP19236282A JPS5982313A (ja)	1982-11-04	1982-11-04	体内脂質減少剤

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP19236282A JPS5982313A (ja)	1982-11-04	1982-11-04	体内脂質減少剤

Publications (2)

Publication Number	Publication Date
JPS5982313A JPS5982313A (ja)	1984-05-12
JPS6260369B2 true JPS6260369B2 (de)	1987-12-16

Family

ID=16290014

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP19236282A Granted JPS5982313A (ja)	1982-11-04	1982-11-04	体内脂質減少剤

Country Status (1)

Country	Link
JP (1)	JPS5982313A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008120813A1 (ja)	2007-04-03	2008-10-09	Mitsubishi Tanabe Pharma Corporation	ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005247752A (ja) *	2004-03-04	2005-09-15	Hokuren Federation Of Agricult Coop:The	血中コレステロール上昇抑制剤
JP2012176907A (ja) *	2011-02-25	2012-09-13	Glico Dairy Products Co Ltd	フラクトオリゴ糖を有効成分とするミオシン軽鎖脱リン酸化促進剤、疾患の予防又は治療剤、及び飲食品
JP7402628B2 (ja)	2019-07-19	2023-12-21	株式会社明治	組成物

1982
- 1982-11-04 JP JP19236282A patent/JPS5982313A/ja active Granted

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008120813A1 (ja)	2007-04-03	2008-10-09	Mitsubishi Tanabe Pharma Corporation	ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用

Also Published As

Publication number	Publication date
JPS5982313A (ja)	1984-05-12

Publication	Publication Date	Title
JP3548102B2 (ja)	2004-07-28	高血圧症予防・治療剤
US5919767A (en)	1999-07-06	Use of pyruvate and anti-cortisol compounds in a method for enhancing physical endurance and athletic endurance in a mammal
EP0342956A2 (de)	1989-11-23	Verwendung von Phytinsäure oder deren Salze zur Behandlung von Hyperlipämie, Obesitas und verwandten Krankheiten
JP2003522822A (ja)	2003-07-29	栄養性の改良されたイヌリン製品
EP0738475A1 (de)	1996-10-23	Alpha-glukosidase Inhibitor, diesen, sowie hauptsächlich Zucker enthaltende Mischung, als Süssstoff für Nahrungs- und Futtermittel
WO1997047209A1 (en)	1997-12-18	Lipid metabolism ameliorants
KR20150145262A (ko)	2015-12-29	에너지 소비의 촉진 및/또는 에너지 소비 기능 저하의 치료 및/또는 예방제, 또는 방법
WO2011077800A1 (ja)	2011-06-30	高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品
JP2012121914A (ja)	2012-06-28	放射線障害軽減剤
JPH01294631A (ja)	1989-11-28	糖尿性疾患治療予防剤及び飲食、し好物
CZ2000324A3 (cs)	2001-03-14	Použití chromu a farmaceutický prostředek
JP2790610B2 (ja)	1998-08-27	α−グルコシダーゼ阻害剤、それを含む糖組成物、甘味料、食品、及び飼料
JPWO2007114499A1 (ja)	2009-08-20	抗脂肪蓄積用組成物
JP2001072583A (ja)	2001-03-21	高脂血症の予防又は治療用組成物
JP7402826B2 (ja)	2023-12-21	がん悪液質において用いる化合物
JPH11255655A (ja)	1999-09-21	神経機能調節剤
JPS6260369B2 (de)	1987-12-16
JP5116072B2 (ja)	2013-01-09	Ｄ−アロースの血糖上昇抑制効果の利用
JP4746281B2 (ja)	2011-08-10	生体内脂質調節剤
CN113712982A (zh)	2021-11-30	一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用
JP4115122B2 (ja)	2008-07-09	血糖値低下剤
JPH06504278A (ja)	1994-05-19	ヒトの高い血糖値を低下させる方法
JP2006213684A (ja)	2006-08-17	インスリン抵抗性改善に用いられる組成物及び健康用食品
JP2021147394A (ja)	2021-09-27	牛樟芝の酒酔い解消及び／又はアルコール代謝増加に用いる用途
JP4520602B2 (ja)	2010-08-11	高血圧症予防・治療剤

JPS6260369B2 - - Google Patents

Info

Links

Landscapes

Priority Applications (1)

Applications Claiming Priority (1)

Publications (2)

Family

ID=16290014

Family Applications (1)

Country Status (1)

Cited By (1)

Families Citing this family (3)

Cited By (1)

Also Published As

Similar Documents